Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 23, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

T-Cell Lymphoma

Interventions

DRUG

Duvelisib

SecuraBio will supply duvelisib

PROCEDURE

Peripheral blood draw

-Prior to transplant, cycle 1 day 1 of duvelisib, and at the time of all imaging studies

Trial Locations (1)

Washington University School of Medicine, St Louis

All Listed Sponsors

collaborator

SecuraBio

INDUSTRY

lead

Washington University School of Medicine

OTHER